Theranostics: Global Markets
Report Scope:
This report provides a comprehensive summary of the theranostics market. It profiles all the major companies present in the market, including revenues, product portfolios and recent activities. It examines the competitive landscape, market trends and market dynamics such as drivers, restraints and opportunities. The report provides historic, current and projected market value. By product type, the market is segmented into theranostics equipment and theranostics agents. Theranostics equipment includes PET/CT, SPECT/CT and others; the theranostics agents studied are diagnostics and therapeutics agents. The regions considered are North America, Europe, Asia-Pacific, and the Rest of the World. The top countries in each region are also profiled. The market is also segmented by application.
Report Includes:
This report provides a comprehensive summary of the theranostics market. It profiles all the major companies present in the market, including revenues, product portfolios and recent activities. It examines the competitive landscape, market trends and market dynamics such as drivers, restraints and opportunities. The report provides historic, current and projected market value. By product type, the market is segmented into theranostics equipment and theranostics agents. Theranostics equipment includes PET/CT, SPECT/CT and others; the theranostics agents studied are diagnostics and therapeutics agents. The regions considered are North America, Europe, Asia-Pacific, and the Rest of the World. The top countries in each region are also profiled. The market is also segmented by application.
Report Includes:
- 45 data tables and 37 additional tables
- An overview of the global markets for theranostics
- Analysis of trends in the global market for theranostics, with revenue data for 2021-2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
- Evaluation of the current market size and revenue growth prospects specific to theranostics, along with a market share analysis by product type, application, and region
- Assessment of current applications for theranostics and emerging applications such as macular degeneration, gynecology, cutaneous hypersensitivity and cardio-respiratory medicines
- Identification of technological and industry trends in each market segment, as well as the manufacturers of products used in theranostics, reagents and instrumentation for theranostics research, as well as suppliers of theranostics-related services
- Assessment of global R&D activity related to theranostics, resulting in the issuance of patents
- A discussion of ESG challenges and ESG practices in the industry
- Analysis of the key companies’ market shares, proprietary technologies and strategic alliances
- Profiles of the leading players, including GE Healthcare, Siemens Healthineers AG, Novartis, Lantheus and Telix Pharmaceuticals Ltd.
CHAPTER 1 EXECUTIVE SUMMARY
Market Outlook
Scope of Report
Market Summary
CHAPTER 2 MARKET OVERVIEW
Overview
PESTLE Analysis
Political
Economic
Social
Technological
Legal
Environmental
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential of New Entrants
Competition in the Industry
Threat of Substitutes
R&D and Regulatory Approval
The Drug Development Process
Drug Discovery
Preclinical Development
Clinical Trials
The New Drug Application Review
NDA Data Review
Clinical Trials for Theranostics
Steps Followed for Radiotherapeutics in Clinical Trials
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Theranostics Replacing Conventional Treatment
Increased Application of Theranostics in Drug Discovery
Prevalence of Chronic Diseases is Increasing the Demand for Personalized Treatment
New Radiotheranostics Driving the Theranostics Market
Rise in Chronic Inflammatory Diseases
Cancer Epidemics in Developing Countries
Market Restraints
High Cost of Theranostics
Market Challenges
Nanotheranostics-Bio Interactions
Challenges of Radiotheranostics
Failure of Radiotherapeutics
Market Opportunities
Theranostics in Cardiovascular Diseases
CHAPTER 4 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Artificial Intelligence in Theranostics
Drug Delivery Using Innovative Material
Boron Neutron Capture Therapy (BNCT)
Luminogen Aggregation-Induced Emission (AIE)
Theranostics in Rheumatoid Arthritis (RA)
CHAPTER 5 MARKET SEGMENTATION ANALYSIS
Segmentation Breakdown
Market Analysis, by Product Type
Theranostics Equipment
Theranostics Agents
Diagnostics Theranostics Agents
Therapeutics Theranostics Agents
Market Analysis, by Application
Etiology of Cancer
Cancer Diagnosis
Cancer Therapeutics
Prostate Cancer
Neuroendocrine Tumors
Thyroid Cancer
Neuroblastoma
Other Diseases
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 6 COMPETITIVE INTELLIGENCE
Strategic Analysis
Clinical Trials Analysis
CHAPTER 7 SUSTAINABILITY IN THERANOSTICS MARKET: AN ESG PERSPECTIVE
Introduction to ESG
Key ESG Issues in the Theranostics Market
Safety of Personnel
Disposal of Radioactive Waste
Nanopollution
Current Status of ESG in the Theranostics Market
ESG Performance Analysis
Concluding Remark from BCC Research
CHAPTER 8 APPENDIX
Methodology
Sources
Acronyms
Company Profiles
BAYER AG
CURIUM PHARMA
GE HEALTHCARE
LANTHEUS
NOVARTIS AG
SIEMENS HEALTHINEERS AG
TELIX PHARMACEUTICALS LTD.
Other Companies
Market Outlook
Scope of Report
Market Summary
CHAPTER 2 MARKET OVERVIEW
Overview
PESTLE Analysis
Political
Economic
Social
Technological
Legal
Environmental
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential of New Entrants
Competition in the Industry
Threat of Substitutes
R&D and Regulatory Approval
The Drug Development Process
Drug Discovery
Preclinical Development
Clinical Trials
The New Drug Application Review
NDA Data Review
Clinical Trials for Theranostics
Steps Followed for Radiotherapeutics in Clinical Trials
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Theranostics Replacing Conventional Treatment
Increased Application of Theranostics in Drug Discovery
Prevalence of Chronic Diseases is Increasing the Demand for Personalized Treatment
New Radiotheranostics Driving the Theranostics Market
Rise in Chronic Inflammatory Diseases
Cancer Epidemics in Developing Countries
Market Restraints
High Cost of Theranostics
Market Challenges
Nanotheranostics-Bio Interactions
Challenges of Radiotheranostics
Failure of Radiotherapeutics
Market Opportunities
Theranostics in Cardiovascular Diseases
CHAPTER 4 EMERGING TECHNOLOGIES AND DEVELOPMENTS
Artificial Intelligence in Theranostics
Drug Delivery Using Innovative Material
Boron Neutron Capture Therapy (BNCT)
Luminogen Aggregation-Induced Emission (AIE)
Theranostics in Rheumatoid Arthritis (RA)
CHAPTER 5 MARKET SEGMENTATION ANALYSIS
Segmentation Breakdown
Market Analysis, by Product Type
Theranostics Equipment
Theranostics Agents
Diagnostics Theranostics Agents
Therapeutics Theranostics Agents
Market Analysis, by Application
Etiology of Cancer
Cancer Diagnosis
Cancer Therapeutics
Prostate Cancer
Neuroendocrine Tumors
Thyroid Cancer
Neuroblastoma
Other Diseases
Geographic Breakdown
Market Analysis, by Region
North America
Europe
Asia-Pacific
Rest of the World
CHAPTER 6 COMPETITIVE INTELLIGENCE
Strategic Analysis
Clinical Trials Analysis
CHAPTER 7 SUSTAINABILITY IN THERANOSTICS MARKET: AN ESG PERSPECTIVE
Introduction to ESG
Key ESG Issues in the Theranostics Market
Safety of Personnel
Disposal of Radioactive Waste
Nanopollution
Current Status of ESG in the Theranostics Market
ESG Performance Analysis
Concluding Remark from BCC Research
CHAPTER 8 APPENDIX
Methodology
Sources
Acronyms
Company Profiles
BAYER AG
CURIUM PHARMA
GE HEALTHCARE
LANTHEUS
NOVARTIS AG
SIEMENS HEALTHINEERS AG
TELIX PHARMACEUTICALS LTD.
Other Companies
LIST OF TABLES
Summary Table : Global Market for Theranostics, by Product Type, Through 2029
Table 1 : Approved Radiopharmaceuticals for Radiotheranostics, 2024
Table 2 : Worldwide Regulatory Authorities, 2024
Table 3 : Dosimetry Pre-therapy and Post-therapy
Table 4 : Global Market for Theranostics, by Product Type, Through 2029
Table 5 : Global Market for Theranostics Equipment, by Type, Through 2029
Table 6 : Global Market for Theranostics Equipment, by Region, Through 2029
Table 7 : Global Market for PET Theranostics Equipment, by Region, Through 2029
Table 8 : Global Market for SPECT Theranostics Equipment, by Region, Through 2029
Table 9 : Global Market for MRI Theranostics Equipment, by Region, Through 2029
Table 10 : Global Market for Other Theranostics Equipment, by Region, Through 2029
Table 11 : Global Market for Theranostics Agents, by Type, Through 2029
Table 12 : Global Market for Theranostics Agents, by Region, Through 2029
Table 13 : Select Theranostics Pair
Table 14 : Properties of Commonly Used Radionuclides in Theranostics
Table 15 : Global Market for Diagnostics Theranostics Agents, by Region, Through 2029
Table 16 : Difference Between Alpha Particles and Beta Particles
Table 17 : Global Market for Therapeutics Theranostics Agents, by Region, Through 2029
Table 18 : Lu-177 Based Active, Completed and Recruiting Studies in the U.S., 2023
Table 19 : Advantages and Disadvantages of Various Cancer Treatments
Table 20 : Global Market for Theranostics Applications, by Type, Through 2029
Table 21 : Global Market for Prostate Cancer Applications in Theranostics, by Region, Through 2029
Table 22 : Global Market for Neuroendocrine Tumor Applications in Theranostics, by Region, Through 2029
Table 23 : Global Market for Thyroid Cancer Applications in Theranostics, by Region, Through 2029
Table 24 : Global Market for Neuroblastoma Applications in Theranostics, by Region, Through 2029
Table 25 : Global Market for Other Disease Applications in Theranostics, by Region, Through 2029
Table 26 : Estimated Number of Cancer Deaths Per Region, 2022 and 2045
Table 27 : North American Market for Theranostics, by Product Type, Through 2029
Table 28 : North American Market for Theranostics Equipment, by Type, Through 2029
Table 29 : North American Market for Theranostics Agents, by Type, Through 2029
Table 30 : North American Market for Theranostics Applications, by Type, Through 2029
Table 31 : North American Market for Theranostics, by Country, Through 2029
Table 32 : Theranostics Centers Needed in the U.S.
Table 33 : European Market for Theranostics, by Product Type, Through 2029
Table 34 : European Market for Theranostics Equipment, by Type, Through 2029
Table 35 : European Market for Theranostics Agents, by Type, Through 2029
Table 36 : European Market for Theranostics Applications, by Type, Through 2029
Table 37 : European Market for Theranostics, by Country, Through 2029
Table 38 : Asia-Pacific Market for Theranostics, by Product Type, Through 2029
Table 39 : Asia-Pacific Market for Theranostics Equipment, by Type, Through 2029
Table 40 : Asia-Pacific Market for Theranostics Agents, by Type, Through 2029
Table 41 : Asia-Pacific Market for Theranostics Applications, by Type, Through 2029
Table 42 : Asia-Pacific Market for Theranostics, by Country, Through 2029
Table 43 : Rest of the World Market for Theranostics, by Product Type, Through 2029
Table 44 : Rest of the World Market for Theranostics Equipment, by Type, Through 2029
Table 45 : Rest of the World Market for Theranostics Agents, by Type, Through 2029
Table 46 : Rest of the World Market for Theranostics Applications, by Type, Through 2029
Table 47 : Market Ranking, Theranostics Agents
Table 48 : Strategic Analysis: Theranostics Market, 2021–2024
Table 49 : Targeted Radioligands Therapy in Clinical Trials, 2024
Table 50 : The Three Pillars of ESG
Table 51 : ESG Ranking of Leading Theranostics Players
Table 52 : ESG Performance and Goals of Various Companies in the Theranostics Market Across Parameters
Table 53 : Report Information Sources
Table 54 : Major Acronyms Used in the Global Theranostics Market
Table 55 : Bayer AG: Company Snapshot
Table 56 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 57 : Bayer AG: Product Portfolio
Table 58 : Bayer AG: News/Key Developments, 2021–2023
Table 59 : Curium Pharma: Company Snapshot
Table 60 : Curium Pharma: Product Portfolio
Table 61 : GE Healthcare: Company Snapshot
Table 62 : GE Healthcare: Financial Performance, FY 2022 and 2023
Table 63 : GE Healthcare: Product Portfolio
Table 64 : GE Healthcare: News/Key Developments, 2023–2024
Table 65 : Lantheus: Company Snapshot
Table 66 : Lantheus: Financial Performance, FY 2022 and 2023
Table 67 : Lantheus: Product Portfolio
Table 68 : Lantheus: News/Key Developments, 2023–2024
Table 69 : Novartis AG: Company Snapshot
Table 70 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 71 : Novartis AG: Product Portfolio
Table 72 : Novartis AG: News/Key Developments, 2022
Table 73 : Siemens Healthineers AG: Company Snapshot
Table 74 : Siemens Healthineers AG: Financial Performance, FY 2022 and 2023
Table 75 : Siemens Healthineers AG: Product Portfolio
Table 76 : Siemens Healthineers AG: News/Key Developments, 2022
Table 77 : Telix Pharmaceutical Ltd.: Company Snapshot
Table 78 : Telix Pharmaceutical Ltd.: Financial Performance, FY 2022 and 2023
Table 79 : Telix Pharmaceutical Ltd.: Product Portfolio
Table 80 : Telix Pharmaceutical Ltd.: News/Key Developments, 2022–2024
Table 81 : Upcoming Startups in The Field of Theranostics
Summary Table : Global Market for Theranostics, by Product Type, Through 2029
Table 1 : Approved Radiopharmaceuticals for Radiotheranostics, 2024
Table 2 : Worldwide Regulatory Authorities, 2024
Table 3 : Dosimetry Pre-therapy and Post-therapy
Table 4 : Global Market for Theranostics, by Product Type, Through 2029
Table 5 : Global Market for Theranostics Equipment, by Type, Through 2029
Table 6 : Global Market for Theranostics Equipment, by Region, Through 2029
Table 7 : Global Market for PET Theranostics Equipment, by Region, Through 2029
Table 8 : Global Market for SPECT Theranostics Equipment, by Region, Through 2029
Table 9 : Global Market for MRI Theranostics Equipment, by Region, Through 2029
Table 10 : Global Market for Other Theranostics Equipment, by Region, Through 2029
Table 11 : Global Market for Theranostics Agents, by Type, Through 2029
Table 12 : Global Market for Theranostics Agents, by Region, Through 2029
Table 13 : Select Theranostics Pair
Table 14 : Properties of Commonly Used Radionuclides in Theranostics
Table 15 : Global Market for Diagnostics Theranostics Agents, by Region, Through 2029
Table 16 : Difference Between Alpha Particles and Beta Particles
Table 17 : Global Market for Therapeutics Theranostics Agents, by Region, Through 2029
Table 18 : Lu-177 Based Active, Completed and Recruiting Studies in the U.S., 2023
Table 19 : Advantages and Disadvantages of Various Cancer Treatments
Table 20 : Global Market for Theranostics Applications, by Type, Through 2029
Table 21 : Global Market for Prostate Cancer Applications in Theranostics, by Region, Through 2029
Table 22 : Global Market for Neuroendocrine Tumor Applications in Theranostics, by Region, Through 2029
Table 23 : Global Market for Thyroid Cancer Applications in Theranostics, by Region, Through 2029
Table 24 : Global Market for Neuroblastoma Applications in Theranostics, by Region, Through 2029
Table 25 : Global Market for Other Disease Applications in Theranostics, by Region, Through 2029
Table 26 : Estimated Number of Cancer Deaths Per Region, 2022 and 2045
Table 27 : North American Market for Theranostics, by Product Type, Through 2029
Table 28 : North American Market for Theranostics Equipment, by Type, Through 2029
Table 29 : North American Market for Theranostics Agents, by Type, Through 2029
Table 30 : North American Market for Theranostics Applications, by Type, Through 2029
Table 31 : North American Market for Theranostics, by Country, Through 2029
Table 32 : Theranostics Centers Needed in the U.S.
Table 33 : European Market for Theranostics, by Product Type, Through 2029
Table 34 : European Market for Theranostics Equipment, by Type, Through 2029
Table 35 : European Market for Theranostics Agents, by Type, Through 2029
Table 36 : European Market for Theranostics Applications, by Type, Through 2029
Table 37 : European Market for Theranostics, by Country, Through 2029
Table 38 : Asia-Pacific Market for Theranostics, by Product Type, Through 2029
Table 39 : Asia-Pacific Market for Theranostics Equipment, by Type, Through 2029
Table 40 : Asia-Pacific Market for Theranostics Agents, by Type, Through 2029
Table 41 : Asia-Pacific Market for Theranostics Applications, by Type, Through 2029
Table 42 : Asia-Pacific Market for Theranostics, by Country, Through 2029
Table 43 : Rest of the World Market for Theranostics, by Product Type, Through 2029
Table 44 : Rest of the World Market for Theranostics Equipment, by Type, Through 2029
Table 45 : Rest of the World Market for Theranostics Agents, by Type, Through 2029
Table 46 : Rest of the World Market for Theranostics Applications, by Type, Through 2029
Table 47 : Market Ranking, Theranostics Agents
Table 48 : Strategic Analysis: Theranostics Market, 2021–2024
Table 49 : Targeted Radioligands Therapy in Clinical Trials, 2024
Table 50 : The Three Pillars of ESG
Table 51 : ESG Ranking of Leading Theranostics Players
Table 52 : ESG Performance and Goals of Various Companies in the Theranostics Market Across Parameters
Table 53 : Report Information Sources
Table 54 : Major Acronyms Used in the Global Theranostics Market
Table 55 : Bayer AG: Company Snapshot
Table 56 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 57 : Bayer AG: Product Portfolio
Table 58 : Bayer AG: News/Key Developments, 2021–2023
Table 59 : Curium Pharma: Company Snapshot
Table 60 : Curium Pharma: Product Portfolio
Table 61 : GE Healthcare: Company Snapshot
Table 62 : GE Healthcare: Financial Performance, FY 2022 and 2023
Table 63 : GE Healthcare: Product Portfolio
Table 64 : GE Healthcare: News/Key Developments, 2023–2024
Table 65 : Lantheus: Company Snapshot
Table 66 : Lantheus: Financial Performance, FY 2022 and 2023
Table 67 : Lantheus: Product Portfolio
Table 68 : Lantheus: News/Key Developments, 2023–2024
Table 69 : Novartis AG: Company Snapshot
Table 70 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 71 : Novartis AG: Product Portfolio
Table 72 : Novartis AG: News/Key Developments, 2022
Table 73 : Siemens Healthineers AG: Company Snapshot
Table 74 : Siemens Healthineers AG: Financial Performance, FY 2022 and 2023
Table 75 : Siemens Healthineers AG: Product Portfolio
Table 76 : Siemens Healthineers AG: News/Key Developments, 2022
Table 77 : Telix Pharmaceutical Ltd.: Company Snapshot
Table 78 : Telix Pharmaceutical Ltd.: Financial Performance, FY 2022 and 2023
Table 79 : Telix Pharmaceutical Ltd.: Product Portfolio
Table 80 : Telix Pharmaceutical Ltd.: News/Key Developments, 2022–2024
Table 81 : Upcoming Startups in The Field of Theranostics
LIST OF FIGURES
Summary Figure : Global Market for Theranostics, by Product Type, 2021–2029
Figure 1 : Theranostics Workflow
Figure 2 : Components of the Drug Approval Process
Figure 3 : Preclinical and Clinical Trials Phases
Figure 4 : Clinical Trials Radionuclide Pictorial Representative, 2024
Figure 5 : Market Dynamics of Theranostics
Figure 6 : Disadvantages of Chemotherapy Treatment
Figure 7 : Drug Development Cost, 2002 and 2022
Figure 8 : Global Market Shares of Theranostics, by Product Type, 2023
Figure 9 : Global Market Shares of Theranostics, by Product Type, 2029
Figure 10 : Global Market Shares of Theranostics Equipment, by Type, 2023
Figure 11 : Global Market Shares of Theranostics Agents, by Type, 2023
Figure 12 : Schematic Representation of Radionuclide Therapy
Figure 13 : Schematic Representation of Radionuclide Therapy
Figure 14 : Etiology of Cancer
Figure 15 : Cancer Diagnostics Methods
Figure 16 : Types of Imaging
Figure 17 : Asia-Pacific Cancer Incidence, 2008 and 2030
Figure 18 : Global Market Shares of Theranostics Instruments, by Installation Base, 2024
Figure 19 : Share of Clinical Trials, by Recruiting Status, 2024
Figure 20 : Share of Clinical Trials, by Type of Indication, 2024
Figure 21 : Share of Clinical Trials, by Phase, 2024
Figure 22 : Share of Clinical Trials, by Type of Funder, 2024
Figure 23 : Share of Clinical Trials, by Gender, 2024
Figure 24 : The Most Used Radioisotopes in Theranostics and Radioligand Clinical Trials, 2024
Figure 25 : ESG Concerns in the Theranostics Market
Figure 26 : Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 27 : Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 28 : GE Healthcare: Revenue Share, by Business Unit, FY 2023
Figure 29 : GE Healthcare: Revenue Share, by Country/Region, FY 2023
Figure 30 : Lantheus: Revenue Share, by Business Unit, FY 2023
Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 33 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2023
Figure 34 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2023
Figure 35 : Telix Pharmaceutical Ltd.: Revenue Share, by Business Unit, FY 2023
Summary Figure : Global Market for Theranostics, by Product Type, 2021–2029
Figure 1 : Theranostics Workflow
Figure 2 : Components of the Drug Approval Process
Figure 3 : Preclinical and Clinical Trials Phases
Figure 4 : Clinical Trials Radionuclide Pictorial Representative, 2024
Figure 5 : Market Dynamics of Theranostics
Figure 6 : Disadvantages of Chemotherapy Treatment
Figure 7 : Drug Development Cost, 2002 and 2022
Figure 8 : Global Market Shares of Theranostics, by Product Type, 2023
Figure 9 : Global Market Shares of Theranostics, by Product Type, 2029
Figure 10 : Global Market Shares of Theranostics Equipment, by Type, 2023
Figure 11 : Global Market Shares of Theranostics Agents, by Type, 2023
Figure 12 : Schematic Representation of Radionuclide Therapy
Figure 13 : Schematic Representation of Radionuclide Therapy
Figure 14 : Etiology of Cancer
Figure 15 : Cancer Diagnostics Methods
Figure 16 : Types of Imaging
Figure 17 : Asia-Pacific Cancer Incidence, 2008 and 2030
Figure 18 : Global Market Shares of Theranostics Instruments, by Installation Base, 2024
Figure 19 : Share of Clinical Trials, by Recruiting Status, 2024
Figure 20 : Share of Clinical Trials, by Type of Indication, 2024
Figure 21 : Share of Clinical Trials, by Phase, 2024
Figure 22 : Share of Clinical Trials, by Type of Funder, 2024
Figure 23 : Share of Clinical Trials, by Gender, 2024
Figure 24 : The Most Used Radioisotopes in Theranostics and Radioligand Clinical Trials, 2024
Figure 25 : ESG Concerns in the Theranostics Market
Figure 26 : Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 27 : Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 28 : GE Healthcare: Revenue Share, by Business Unit, FY 2023
Figure 29 : GE Healthcare: Revenue Share, by Country/Region, FY 2023
Figure 30 : Lantheus: Revenue Share, by Business Unit, FY 2023
Figure 31 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 32 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 33 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2023
Figure 34 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2023
Figure 35 : Telix Pharmaceutical Ltd.: Revenue Share, by Business Unit, FY 2023
